The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
about
Monitoring anticoagulant therapy with new oral agentsThe case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit-risk ratioDabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional ExperienceDifferential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatranNew oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectivenessSpotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatranDirect Thrombin Inhibitors Prevent Left Atrial Remodeling Associated With Heart Failure in RatsLong-term prescribing of new oral anticoagulantsEpidemiology, diagnosis, and management of atrial fibrillation in womenRecent advances in the development of specific antidotes for target-specific oral anticoagulantsReal Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran.Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugsCorrelation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C.Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants.Recent advances in preventing stroke recurrence.Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective.Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin timeCoagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatranQuality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service--results from the prospective, multi-center, observational cohort study thrombEVALMeasurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.Enhanced elimination of dabigatran through extracorporeal methods.Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort study.Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug ConcentrationsCurrent and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? No.Perioperative management of antithrombotic and antiplatelet therapyHelsinki experience on nonvitamin K oral anticoagulants for treating cervical artery dissection.Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation.Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?Clinical utility of dabigatran in United Arab Emirates. A pharmacovigilance study.Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting.Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.Direct oral anticoagulant drug level testing in clinical practice: A single institution experience.Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTHNon-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011-2015 in DenmarkIdentification of carboxylesterase-dependent dabigatran etexilate hydrolysis.Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillationBenefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation.Acute stroke in patients on new direct oral anticoagulants: how to manage, how to treat?
P2860
Q26771728-4EBFDBB1-1A1F-41BB-9E50-2DBFB03835EEQ26776239-1A862166-6AB0-407A-A2D3-C303DFF4EDF7Q26783457-A7BD4C1F-737D-4C67-B54F-8AD8387E508DQ26799710-B59047F3-6248-4BA0-BCF4-3A270BCF0A1EQ26863548-034304EA-568F-4348-A5E0-722BAE9FA10DQ28066262-2E10B8BB-EF8B-4A30-805D-6AE6BA1FFA78Q28068706-4F998627-B42E-475D-BD68-5C0416763A83Q28069821-F2273B25-F4AF-42E6-8C85-A44BF566FDAFQ28083655-FB6DA510-2263-4CEE-88AE-7D089B498FC4Q28256340-9842119D-1927-4420-B0FA-4DEF0BBC95F5Q31098679-03EA944C-CFF8-4731-A74A-B0F2287AEC0BQ33730353-C1D1544F-C824-4452-844B-16D942D9B65AQ33804810-9DD5B8A0-2FCA-4257-9C0D-307F7FCA7C96Q33854667-583A4E9D-4750-48AC-82E3-9FF62ABE33E6Q33873364-3EA59EE7-F232-4028-842B-AE2187BF6A8CQ34099930-033D33F2-139E-4938-A863-C1BDEEAAE496Q34206252-11AE9B33-E5C8-4BD0-AE3E-C2A3BB869A16Q34571082-F9FCB901-5180-425E-96F3-E2EB2CAF9FADQ34571099-D4C23A10-CB0E-483F-A8EF-3FB5AC080FE7Q35099559-43680CDC-5E71-4569-8521-E72F7721AE5BQ35154142-4CE113D3-347A-41F3-AAD8-DBD2C524823EQ35210137-CEF64C09-664F-43D8-859F-250DCF9E5B7CQ35640209-FA7C495C-ADF8-40B7-BB58-40B62C748734Q35674404-4BC00A4F-8FA4-4609-8FB7-D5BFADAAAE98Q35683869-857BB744-0DCF-4723-A1E3-0747233C7ACEQ35689817-970B5C2F-A04D-4350-8A8C-1DE004CFEE16Q35758792-7955649B-85FD-4C65-9AE1-53418262B4D9Q36023804-84F2E4ED-2D18-4A69-835C-FCE7CDD3F04DQ36113146-1154605E-4D62-46E8-AE50-D0787BBB1E7FQ36331126-FBF949BE-C04A-4592-B166-0F086E5FACC3Q36356624-36AF1544-2647-49D0-B715-AD6137630493Q36875879-87E108DB-7188-4F7E-8910-3C76900DE6D8Q36956814-052C26F6-4FA0-494D-9A98-E85D9C91ED2DQ37037385-4E8E0500-7682-406E-9D84-7BF1A706EBB3Q37073792-A9467FB9-5347-4A83-A6B5-89BCCE24BC14Q37166491-78FAB04A-333F-4B82-B7D8-9557BB628219Q37550678-B161B069-12FB-436B-BFFC-69D7F0E4286AQ37578065-4BA6C1B9-1C54-454D-B309-3FACA857EC39Q38200587-AB5D2BC8-E90B-43A7-9A65-BE198BAAD17EQ38228428-98D7ECE2-4886-40A2-9B54-1DC7401DA9B7
P2860
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The effect of dabigatran plasm ...... Term Anticoagulation Therapy).
@ast
The effect of dabigatran plasm ...... Term Anticoagulation Therapy).
@en
The effect of dabigatran plasm ...... tion patients: the RE-LY Trial
@nl
type
label
The effect of dabigatran plasm ...... Term Anticoagulation Therapy).
@ast
The effect of dabigatran plasm ...... Term Anticoagulation Therapy).
@en
The effect of dabigatran plasm ...... tion patients: the RE-LY Trial
@nl
prefLabel
The effect of dabigatran plasm ...... Term Anticoagulation Therapy).
@ast
The effect of dabigatran plasm ...... Term Anticoagulation Therapy).
@en
The effect of dabigatran plasm ...... tion patients: the RE-LY Trial
@nl
P2093
P50
P921
P1476
The effect of dabigatran plasm ...... Term Anticoagulation Therapy).
@en
P2093
Gerhard Nehmiz
Michael D Ezekowitz
Paul A Reilly
RE-LY Investigators
Sebastian Haertter
Stuart J Connolly
Susan Wang
Thorsten Lehr
P304
P356
10.1016/J.JACC.2013.07.104
P407
P577
2013-09-27T00:00:00Z